If medication is stopped without maintaining lifestyle changes, many people regain some of the lost weight
This may be of benefit for anyone with MCAS, and clinical trials are looking at the effectiveness of different doses.[ref][ref] Dementia prevention: Studies using data from diabetes patients showed a significant decrease in dementia for those on GLP-1s vs other diabetes medications
Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are both FDA-approved specifically for weight management in adults with obesity or overweight with a weight-related condition regardless of whether diabetes is present
Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe
Official Injection Sites for GLP-1 Medications According to their FDA-approved prescribing information, GLP-1 medications semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) are administered as injections just under the skin (subcutaneous) in three areas: Abdomen avoid the 2 inches (5 cm) directly around the navel Thigh outer/front thigh Upper arm back of the upper arm All four FDA labels (Ozempic 1 , Zepbound 2 , Mounjaro 3 , Wegovy 4 ) explicitly state that patients should rotate injection sites with each dose
The American College of Cardiology/American Heart Association/The Obesity Society guidelines emphasize individualized treatment plans incorporating lifestyle modification, behavioral therapy, pharmacotherapy when appropriate, and metabolic/bariatric surgery for eligible patients